Core Insights - QuidelOrtho has entered a strategic supply agreement with Lifotronic Technology to expand its global immunoassay portfolio, focusing on high-throughput and low-to-mid volume immunoassay analyzers [1] - The partnership aims to provide cost-efficient and scalable diagnostic solutions in selected international markets outside the US, enhancing QuidelOrtho's competitive edge [1][4] Product Expansion - The agreement will introduce over 25 new assays not currently available on QuidelOrtho's VITROS system, increasing the total number of assays on the new platforms to more than 70 [2] - This expansion is designed to meet broader tender requirements and cater to various laboratory environments, from low-volume solutions to larger settings [2][3] Market Impact - Laboratories will benefit from the expanded offering, which addresses menu gaps and enhances competitiveness in international tenders by providing more flexible system options [3] - QuidelOrtho's senior vice-president emphasized that the collaboration will accelerate the introduction of scalable testing solutions, aligning with the company's long-term innovation strategy in core growth markets [4]

Core Insights - Biodesix, Inc. reported preliminary financial results for Q4 and fiscal year 2025, with estimated revenues of $28.8 million for Q4 and $88.5 million for the full year, representing increases of 41% and 24% respectively [1][2][7] Financial Performance - The company achieved a strong Q4, exceeding its revenue guidance of $84-$86 million for the full year [3] - Lung Diagnostics revenue was estimated at $25.2 million for Q4 and $79.2 million for fiscal 2025, marking increases of 47% and 22% respectively [7] - Test volumes for Lung Diagnostics reached 18,000 in Q4 and 62,600 for the full year, reflecting growth of 23% and 15% year-over-year [7] - Development Services revenue was estimated at $3.6 million for Q4 and $9.3 million for fiscal 2025, showing increases of 13% and 41% respectively [7] Cash Position - As of December 31, 2025, Biodesix reported cash and cash equivalents of $19.0 million, a 14% increase from Q3 2025, which included $2.3 million in at-the-market proceeds [7]